Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLGN NASDAQ:ICCM NASDAQ:POAI NYSE:RVP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLGNCollPlant Biotechnologies$0.43-1.1%$0.48$0.27▼$4.98$6.34M1.4787,258 shs38,608 shsICCMIceCure Medical$0.22-4.3%$0.40$0.22▼$1.40$18.67M0.47588,253 shs589,841 shsPOAIPredictive Oncology$5.85+4.5%$3.88$0.71▼$16.54$19.86M1.35473,545 shs345,832 shsRVPRetractable Technologies$0.67+4.7%$0.68$0.60▼$1.14$20.06M1.2559,144 shs135,232 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLGNCollPlant Biotechnologies-1.14%+10.55%+21.79%-31.42%-74.87%ICCMIceCure Medical-4.26%-8.33%-38.72%-61.25%-78.85%POAIPredictive Oncology0.00%+3.17%+66.19%+139.75%-63.89%RVPRetractable Technologies+4.69%-1.96%0.00%-5.90%-6.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLGNCollPlant Biotechnologies$0.43-1.1%$0.48$0.27▼$4.98$6.34M1.4787,258 shs38,608 shsICCMIceCure Medical$0.22-4.3%$0.40$0.22▼$1.40$18.67M0.47588,253 shs589,841 shsPOAIPredictive Oncology$5.85+4.5%$3.88$0.71▼$16.54$19.86M1.35473,545 shs345,832 shsRVPRetractable Technologies$0.67+4.7%$0.68$0.60▼$1.14$20.06M1.2559,144 shs135,232 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLGNCollPlant Biotechnologies-1.14%+10.55%+21.79%-31.42%-74.87%ICCMIceCure Medical-4.26%-8.33%-38.72%-61.25%-78.85%POAIPredictive Oncology0.00%+3.17%+66.19%+139.75%-63.89%RVPRetractable Technologies+4.69%-1.96%0.00%-5.90%-6.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLGNCollPlant Biotechnologies 2.00Hold$11.502,544.89% UpsideICCMIceCure Medical 2.40Hold$2.09850.00% UpsidePOAIPredictive Oncology 1.00SellN/AN/ARVPRetractable Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CLGN, POAI, RVP, and ICCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026ICCMIceCure Medical Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $1.005/4/2026ICCMIceCure Medical Alliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/21/2026ICCMIceCure Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CLGNCollPlant Biotechnologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLGNCollPlant Biotechnologies$2.37M2.64N/AN/A$0.48 per share0.91ICCMIceCure Medical$3.57M5.01N/AN/A$0.12 per share1.83POAIPredictive Oncology$1.66M11.93N/AN/A($0.46) per share-12.72RVPRetractable Technologies$38.27M0.52$0.01 per share48.25$3.31 per share0.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLGNCollPlant Biotechnologies-$11.49M-$1.35N/AN/AN/A-353.70%-161.69%-109.44%5/21/2026 (Estimated)ICCMIceCure Medical-$15.06M-$0.24N/AN/AN/A-441.60%-211.73%-119.13%N/APOAIPredictive Oncology-$12.66M-$13.50N/AN/AN/A-5,065.23%-732.73%-235.55%N/ARVPRetractable Technologies-$7.01M-$0.21N/AN/AN/A-41.11%-17.15%-9.33%N/ALatest CLGN, POAI, RVP, and ICCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026CLGNCollPlant Biotechnologies-$0.2374N/AN/AN/A$0.46 millionN/A5/12/2026Q1 2026ICCMIceCure Medical-$0.03-$0.06-$0.03$0.06$1.34 million$0.91 million3/17/2026Q4 2025ICCMIceCure Medical-$0.04-$0.06-$0.02-$0.0620$1.30 million$1.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLGNCollPlant BiotechnologiesN/AN/AN/AN/AN/AICCMIceCure MedicalN/AN/AN/AN/AN/APOAIPredictive OncologyN/AN/AN/AN/AN/ARVPRetractable TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLGNCollPlant BiotechnologiesN/A2.532.31ICCMIceCure MedicalN/A2.521.97POAIPredictive OncologyN/A0.010.01RVPRetractable Technologies0.018.575.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLGNCollPlant Biotechnologies21.69%ICCMIceCure Medical0.62%POAIPredictive Oncology9.04%RVPRetractable Technologies7.58%Insider OwnershipCompanyInsider OwnershipCLGNCollPlant Biotechnologies9.60%ICCMIceCure Medical2.44%POAIPredictive Oncology1.21%RVPRetractable Technologies59.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLGNCollPlant Biotechnologies7014.41 million13.03 millionOptionableICCMIceCure Medical6081.24 million79.26 millionNot OptionablePOAIPredictive Oncology303.39 million3.35 millionNot OptionableRVPRetractable Technologies24029.94 million13.47 millionOptionableCLGN, POAI, RVP, and ICCM HeadlinesRecent News About These CompaniesRetractable Technologies, Inc. Results for the Period Ended March 31, 2026May 15, 2026 | businesswire.comRetractable Technologies Shareholders Reelect Class 2 DirectorsMay 13, 2026 | tipranks.comCritical Survey: Retractable Technologies (NYSE:RVP) & Interpace Biosciences (OTCMKTS:IDXG)May 12, 2026 | americanbankingnews.comRetractable Technologies, Inc. Announces Workforce ReductionApril 9, 2026 | businesswire.comRetractable Technologies Analyst Ratings and Price Targets | AMEX:RVP | BenzingaApril 9, 2026 | benzinga.comRVP Stock Plunges Post Q4 Earnings Despite Revenue GrowthApril 1, 2026 | zacks.comRetractable Technologies Declares Preferred Dividend Amid Tariff PressuresMarch 27, 2026 | tipranks.comRetractable Technologies: Q4 Earnings SnapshotMarch 27, 2026 | houstonchronicle.comHRetractable Technologies, Inc. Reports Results for 2025March 27, 2026 | businesswire.comRetractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock ShareholdersMarch 27, 2026 | businesswire.comRVP Stock Rises Post Q3 Earnings Despite Tariff and Cost PressuresNovember 20, 2025 | zacks.comRetractable Technologies, Inc. Results for the Periods Ended September 30, 2025November 14, 2025 | businesswire.comRetractable Technologies, Inc. Receives Innovative Technology Designation from Vizient for EasyPoint Blood Collection Tube Holder with NeedleNovember 14, 2025 | businesswire.comRetractable Technologies (NYSE:RVP) CEO Thomas Shaw Purchases 15,000 SharesNovember 1, 2025 | insidertrades.comInsider Buying: Retractable Technologies (NYSE:RVP) CEO Acquires 35,000 Shares of StockOctober 30, 2025 | insidertrades.comInsider Buying: Retractable Technologies (NYSE:RVP) CEO Buys 34,506 Shares of StockOctober 29, 2025 | insidertrades.comRetractable Technologies (NYSE:RVP) CEO Acquires $13,209.72 in StockOctober 16, 2025 | insidertrades.comRetractable Technologies (NYSE:RVP) CEO Thomas Shaw Buys 30,000 SharesOctober 10, 2025 | insidertrades.comRetractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock ShareholdersSeptember 30, 2025 | businesswire.comThomas Shaw Purchases 17,500 Shares of Retractable Technologies (NYSE:RVP) StockSeptember 26, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLGN, POAI, RVP, and ICCM Company DescriptionsCollPlant Biotechnologies NASDAQ:CLGN$0.43 -0.01 (-1.14%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$0.44 +0.00 (+0.51%) As of 07:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.IceCure Medical NASDAQ:ICCM$0.22 -0.01 (-4.26%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$0.22 0.00 (-0.45%) As of 06:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.Predictive Oncology NASDAQ:POAI$5.85 +0.25 (+4.46%) As of 05/15/2026Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.Retractable Technologies NYSE:RVP$0.67 +0.03 (+4.69%) Closing price 05/18/2026 03:59 PM EasternExtended Trading$0.70 +0.03 (+5.22%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. It distributes its products through general line and specialty distributor; international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? 5 Robotics Stocks to Watch as Physical AI Builds Momentum Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1 Peloton Stock Gives Back Gains After Upbeat Earnings Report 3 Infrastructure Stocks Fueling the Data Center Building Boom MarketBeat Week in Review – 05/11 - 05/15 Insider Buying Says Upstart Isn’t Down for the Count Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
